Moderna, Inc. (NASDAQ:MRNA)

PRESS RELEASE

published on 09/17/2024 at 17:00, 1 year 7 months ago

Moderna Receives Health Canada Approval For Updated COVID-19 Vaccine Targeting KP.2 Variant Of SARS-COV-2 For Ages Six Months And Older
Moderna's SPIKEVAX® KP.2 variant COVID-19 vaccine authorized in Canada for 2024-2025 season to protect against COVID-19 strains. Delivery to begin promptly for vaccination campaigns

COVID-19 Vaccine Health Canada Moderna Spikevax Vaccination Campaigns
BRIEF

published on 09/12/2024 at 12:05, 1 year 7 months ago

Moderna R&D Day Highlights Progress and Strategic Priorities

COVID-19 Vaccine Financial Outlook Vaccine Approvals Moderna Updates R&D Strategy
PRESS RELEASE

published on 09/12/2024 at 12:00, 1 year 7 months ago

Moderna R&D Day Highlights Progress and Strategic Priorities
Moderna, Inc. announces program updates focusing on ten product approvals through 2027, submission of next-gen COVID vaccine and flu/COVID combo vaccine in 2024, positive Phase 3 results for RSV vaccine, and cost efficiency improvements

Moderna Vaccine Phase 3 Results Product Approvals R&D Expense Reduction
BRIEF

published on 09/09/2024 at 13:05, 1 year 7 months ago

Moderna’s Canadian Manufacturing Facility Receives Drug Establishment License From Health Canada

Health Canada Moderna MRNA Vaccines Laval Facility Drug Establishment License
PRESS RELEASE

published on 09/09/2024 at 13:00, 1 year 7 months ago

Moderna’s Canadian Manufacturing Facility Receives Drug Establishment License From Health Canada
Moderna's Laval facility in Canada attains Drug Establishment License, a key step towards onshore mRNA vaccine production by 2025. This milestone boosts national vaccine supply

Canada Manufacturing Facility Moderna MRNA Vaccines Drug Establishment License
BRIEF

published on 09/05/2024 at 14:05, 1 year 7 months ago

EMA Recommends Authorization of Moderna's Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant JN.1

Authorization COVID-19 Vaccine Moderna EMA SARS-CoV-2 Variant
PRESS RELEASE

published on 09/05/2024 at 14:00, 1 year 7 months ago

EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1
Moderna's updated COVID-19 mRNA vaccine targeting SARS-CoV-2 variant JN.1 receives positive opinion from CHMP for European Commission authorization decision for 2024-2025 vaccination season

COVID-19 Vaccine European Commission Moderna MRNA Spikevax
BRIEF

published on 09/03/2024 at 14:35, 1 year 7 months ago

Moderna Receives MHRA Authorization for Updated COVID-19 Vaccine Targeting JN.1 Variant

COVID-19 Moderna Vaccine JN.1 Variant MHRA
PRESS RELEASE

published on 09/03/2024 at 14:30, 1 year 7 months ago

Moderna Receives Medicines And Healthcare Products Regulatory Agency (MHRA) Authorization For Updated COVID-19 Vaccine Targeting SARS-COV-2 Variant JN.1
MHRA authorizes Moderna's updated COVID-19 vaccine targeting JN.1 variant. Available for NHS and private purchase in the UK. Follows WHO recommendation for JN.1 subvariants

COVID-19 Vaccine Moderna JN.1 Variant MHRA Authorization Private Purchase
BRIEF

published on 09/02/2024 at 13:05, 1 year 8 months ago

Taiwan FDA Approves Moderna’s COVID-19 Vaccine Targeting SARS-CoV-2 Variant JN.1

COVID-19 Vaccine Moderna Spikevax Taiwan FDA SARS-CoV-2 JN.1

Published on 05/02/2026 at 21:00, 11 hours 37 minutes ago

GECC Subsidiary Provides Update on its Lawsuit for Damages Against the Lender of the Atmosphere Project
Published on 05/02/2026 at 01:30, 1 day 7 hours ago

Uraniumx Reports Strong Financial Position Ahead of Spring Drill Program
Published on 05/02/2026 at 00:50, 1 day 7 hours ago

CoTec Announces Annual Stock Option, Restricted Share Unit And Deferred Share Unit Grants
Published on 05/02/2026 at 00:00, 1 day 8 hours ago

Redwood AI Announces Enhanced AI Models, Increasing Evaluated Chemical Reactions Following Preliminary Results from UBC Collaboration
Published on 05/02/2026 at 00:00, 1 day 8 hours ago

Onco-Innovations Expands Manufacturing Scale-Up of Its PNKP Inhibitor Technology with Dalton Pharma Services, Advancing Multi-Kilogram Non-GMP Synthesis to Support IND-Enabling Studies

View all ACCESSWIRE

Published on 05/03/2026 at 04:45, 3 hours 52 minutes ago

GWM Unveils World-Class Safety & Testing Facilities: Safety Built on Data, Not Hype
Published on 05/02/2026 at 15:35, 17 hours 2 minutes ago

Ecuador's banana sector renews labor agreement, with jobs meeting global standards
Published on 05/01/2026 at 19:23, 1 day 13 hours ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 05/01/2026 at 18:40, 1 day 13 hours ago

Holding(s) in Company
Published on 05/01/2026 at 17:47, 1 day 14 hours ago

Key Figures 30.04.2026

View all EQS

Published on 04/30/2026 at 20:00, 2 days 12 hours ago

AMA Corp PLC : FY 2025 Earnings & Q1 2026 Revenue
Published on 04/30/2026 at 19:16, 2 days 13 hours ago

AXA announces the results of its Shareholders' Meeting
Published on 04/30/2026 at 19:00, 2 days 13 hours ago

Capital increase through exercise of subscription rights
Published on 04/30/2026 at 18:10, 2 days 14 hours ago

Minutes of the Combined General Meeting held on April 30, 2026
Published on 04/30/2026 at 18:00, 2 days 14 hours ago

TF1 Q1 2026 results - Press release

View all LES ECHOS COMFI WIRE

News